GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Noile-Immune Biotech 4893.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

85

+7.59%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Noile-Immune Biotech

Its shares trade on Tokyo Stock Exchange under the ticker 4893.T. It has been listed since 28 June 2023. In the fiscal year to 31 December 2025, it reported revenue of ¥5.0m and a net loss of ¥793.5m. At that date it held total assets of ¥4.01bn and shareholders' equity of ¥3.93bn.

Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-06-28. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The firm establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
28 Jun 2023

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Noile-Immune Biotech Inc develops CAR-T cell therapy for solid tumors using proprietary technology.
  • The Cancer Immunotherapy Drug Discovery segment combines PRIME technology with therapeutic technologies for solid tumors.
  • The firm establishes a hybrid business model with in-house drug discovery and joint pipeline options.

Weaknesses

  • The company went IPO on 28 June 2023, indicating a relatively recent market entry.
  • Minato-ku, Tokyo-To is the headquarters location, which may limit operational flexibility in other regions.
  • The sector is Health Care, which requires extensive regulatory approval and clinical trial phases.

Opportunities

  • PRIME technology can be licensed to other companies for drug development through the joint pipeline.
  • The hybrid business model allows the firm to take initiative in in-house drug discovery.
  • Solid tumors represent a significant market segment for various gene-modified immuno-cell therapies.

Threats

  • Biotechnology is a highly competitive industry with rapid technological advancements and emerging competitors.
  • Health Care regulations impose strict compliance requirements that could delay product commercialization timelines.
  • Solid tumor treatments face complex biological challenges that may hinder clinical trial success rates.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.